Literature DB >> 35089572

Eukaryotic Aggresomes: Protocols and Tips for Their Production, Purification , and Handling.

Rosa Mendoza1,2, Neus Ferrer-Miralles1,2,3, José Luis Corchero4,5,6.   

Abstract

Aggresomes are insoluble protein aggregates found in eukaryotic cells when the intracellular machinery is overtitered by, for example, the overexpression of a recombinant protein. These protein nanoparticles have become excellent models in studies devoted to elucidate protein aggregation processes in eukaryotic cells, like those involved in "conformational disorders" linked to neurodegenerative diseases. Since the presence of such protein aggregates is a hallmark of these conditions, they constitute an excellent target for new therapeutic approaches for such devastating pathologies. Moreover, and following the pathway opened a few years ago by bacterial inclusion bodies, eukaryotic aggresomes have been proposed as a new type of carrier-free, self-immobilized biocatalysts for use in biotechnology and biomedicine. Altogether, unraveling the characteristics and putative applications of naturally occurring protein aggregates has received an increasing interest during the last years. For that, availability of protocols allowing the production and purification of aggresomes constitute a valuable tool to boost research in the abovementioned fields. In this chapter, we describe both upstream and downstream protocols to obtain aggresomes produced in human cells, using as a model the recombinant human enzyme alpha-galactosidase A (GLA), together with technical tips and advices when working and analyzing eukaryotic aggresomes.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aggresomes; Immobilized biocatalyst; Neurogenerative diseases; Protein nanoparticles

Mesh:

Substances:

Year:  2022        PMID: 35089572     DOI: 10.1007/978-1-0716-1859-2_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

Review 1.  Aggresomes, inclusion bodies and protein aggregation.

Authors:  R R Kopito
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

Review 2.  Aggresomes and Russell bodies. Symptoms of cellular indigestion?

Authors:  R R Kopito; R Sitia
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

Review 3.  Hassles with taking out the garbage: aggravating aggresomes.

Authors:  Rafael Garcia-Mata; Ya-Sheng Gao; Elizabeth Sztul
Journal:  Traffic       Date:  2002-06       Impact factor: 6.215

4.  Biopharmaceutical benchmarks 2018.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2018-12-06       Impact factor: 54.908

5.  Parkin accumulation in aggresomes due to proteasome impairment.

Authors:  Eunsung Junn; Sang Seop Lee; Unsun T Suhr; M Maral Mouradian
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

6.  The formation of biologically active beta-galactosidase inclusion bodies in Escherichia coli.

Authors:  D M Worrall; N H Goss
Journal:  Aust J Biotechnol       Date:  1989-01

7.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

8.  Dynamic association of proteasomal machinery with the centrosome.

Authors:  W C Wigley; R P Fabunmi; M G Lee; C R Marino; S Muallem; G N DeMartino; P J Thomas
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

Review 9.  A Brief Reminder of Systems of Production and Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals.

Authors:  B Owczarek; A Gerszberg; K Hnatuszko-Konka
Journal:  Biomed Res Int       Date:  2019-01-08       Impact factor: 3.411

10.  Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion.

Authors:  Y A Ioannou; D F Bishop; R J Desnick
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.